This information is intended for US healthcare professionals to access current scientific information about J&J Innovative Medicine products. It is prepared by Medical Information and is not intended for promotional purposes, nor to provide medical advice.
Functional high-risk
A retrospective analysis in a large cohort of NDMM patients1
Background/Objective
- To identify if an early relapse after first-line intensive treatment is
associated with poor OS in standard- or high-risk patients
- Relapse was considered early if it occurred within 18 months of starting initial therapy
Key findings
- Early relapse is still strongly associated with reduced survival after an intensive first-line treatment in both high and standard-risk cytogenic groups
Overall survival for patients according to risk status and early or no early relapse
Figure adapted from Corre et al. 2020.
Early relapse is a poor prognostic factor regardless of cytogenetic risk at the time of diagnosis
A retrospective analysis of NDMM patients from the ASH Research Collaborative Data Hub2
Objective
- To define functional high-risk MM by evaluating the prognostic impact of time to progression after first-line therapy (PD1) in the modern induction era
Methods
- Retrospective ASH Research Collaborative Data Hub analysis (1999-2023)
- NDMM treated with triplet/quadruplet induction ± ASCT
- PD1 cut points evaluated (12-36 months)
- Endpoints: TTNT, PFS2, OS; recursive partitioning used
Results
- Progression <30 months associated with worse PFS2 and OS
- 30-month PD1 identified as optimal cutoff
Early progression (<30 months) after modern induction defines functional high-risk MM and is associated with poor downstream outcomes, highlighting an unmet need for earlier identification
ASCT, autologous stem cell transplant; ASH, American Society of Hematology; CI, confidence interval;; HR, hazard ratio; MM, multiple myeloma; NDMM, newly-diagnosed multiple myeloma; NE, not estimable; PD1, duration of response from first line therapy; PFS2, progression free survival 2; R-ISS, revised International Staging System; TTNT, time to next treatment.
1. Corre J, et al. Haematologica. 2020;105:48-483. 2. Paul, et al. Presented at: ASH 2025, Poster presentation 653.
Connect with us
Connect with us
Would you like to clear and leave your conversation? Message history will be lost.